We invest with conviction, guided by strong biological rationale and disciplined execution. Our strategy combines venture creation, early-stage company building, and selective clinical co-investment – always with a focus on translating breakthrough discoveries into transformative medicines.
We partner closely with scientists and founders to shape first experiments, assemble strong teams, and design clear paths to value. Beyond funding, we provide hands-on support across science, development, and strategy, helping companies reach critical milestones that unlock clinical progress and strategic optionality.
Across all stages, our hallmark is deep engagement: bringing discipline to every decision, and ensuring the science we back has the strength to become meaningful medicine.
Where Science Meets Discipline
Europe and the US remain at the heart of our strategy – Europe, where (world-class) science is capital-efficient yet often overlooked and the US, where scale, visibility, and exits accelerate growth. This dual anchor gives our portfolio the best of both worlds: sustainable growth and access to the deepest markets.
Our true compass is science. Wherever breakthrough innovation emerges, we’re ready to help transform it into medicines that change lives.
